ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02182362
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 18, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The main objective was to investigate the safety, tolerability and the pharmacokinetics (PK) of BI 201335 NA in healthy male subjects without Gilbert's syndrome or polymorphism (GS) following oral administration of a single dose (Day 1) and repeated doses (Days 4-24) of 20 mg, 48 mg, 120 mg, and 240 mg. Additionally, the safety, tolerability, and the PK of the highest tolerated dose of BI 201335 NA (determined during the multiple-rising-dose phase) were assessed in healthy male subjects with GS over a 28-day continuous drug administration period.

Condition or disease Intervention/treatment Phase
Healthy Drug: BI 201335 NA Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of 20 mg, 48 mg, 120 mg, and 240 mg Once a Day of BI 201335 NA (Oral Solution) in Healthy Male Subjects, in a Randomized Double Blind, Placebo Controlled Study
Study Start Date : May 2007
Actual Primary Completion Date : February 2008

Arm Intervention/treatment
Experimental: BI 201335 NA in rising doses
single dose of BI 201335 NA on day 1, multiple dosing days 4-24
Drug: BI 201335 NA
Placebo Comparator: Placebo Drug: Placebo
Experimental: BI 201335 NA
highest tolerated dose of BI 201335 on day 1-28 in patients with Gilbert's syndrome
Drug: BI 201335 NA



Primary Outcome Measures :
  1. Number of patients with abnormal findings in physical examination [ Time Frame: Baseline and up to 46 days ]
  2. Number of patients with clinically relevant changes in vital signs (blood pressure (BP), pulse rate (PR)) [ Time Frame: Baseline and up to 32 days ]
  3. Number of patients with clinically relevant changes in 12-lead ECG (electrocardiogram) [ Time Frame: Baseline and up to 32 days ]
  4. Number of patients with clinically relevant changes in clinical laboratory tests (haematology, clinical chemistry, urinalysis) [ Time Frame: Baseline and up to 32 days ]
  5. Incidence of adverse events [ Time Frame: up to day 46 ]
  6. Assessment of tolerability by investigator [ Time Frame: Day 28 or 32 ]

Secondary Outcome Measures :
  1. Cmax (maximum measured concentration of the analyte in plasma) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment ]
  2. tmax (time from dosing to maximum measured concentration of the analyte in plasma) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment ]
  3. AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment ]
  4. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment ]
  5. λz (terminal rate constant in plasma) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment ]
  6. t1/2 (terminal half-life of the analyte in plasma) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment ]
  7. MRTpo (mean residence time of the analyte in the body after single oral administration) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment ]
  8. CL/F (apparent clearance of the analyte in plasma) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment ]
  9. Vz/F (apparent volume of distribution during the terminal phase λz) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment ]
  10. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose ]
  11. tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose ]
  12. Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose ]
  13. AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose ]
  14. λz,ss (terminal rate constant in plasma at steady state) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose ]
  15. t1/2,ss (terminal half-life of the analyte in plasma at steady state) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose ]
  16. MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose ]
  17. CL/F,ss (apparent clearance of the analyte in the plasma at steady state following multiple oral dose administration) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose ]
  18. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following oral administration) [ Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males according to the following criteria:

    • Complete medical history, physical examination, vital signs (Blood Pressure, Pulse Rate), 12-lead ECG (electrocardiogram), and clinical laboratory tests
  • Age ≥18 and Age ≤55 years
  • BMI ≥18.5 and BMI ≤30 kg/m2 (Body Mass Index)
  • Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation

Exclusion Criteria:

  • Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  • Any evidence of a clinically relevant concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Subjects with polymorphisms associated with Gilbert's syndrome will be excluded from the initial 4 groups of the multiple rising dose phase of the study. However, only subjects with Gilbert's polymorphism will be allowed to participate in the last group which will be treated with the highest tolerated dose determined in the multiple rising dose phase of the trial
  • Prior history of jaundice for subjects without Gilbert's polymorphism
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval within 30 days prior to screening until trial completion
  • Participation in another trial with an investigational drug within two months prior to administration or during the trial
  • Smoking (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking during the trial
  • Alcohol abuse (more than 60 g/day)
  • Inability to refrain from alcohol during the trial
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
  • A history of additional risk factors for TdP (Torsades de points) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)

Additional Information:
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02182362     History of Changes
Other Study ID Numbers: 1220.6
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 18, 2014
Last Verified: July 2014